�����ջ���

The temporary program, which runs until the end of 2027, is the first opportunity for most older adults to get GLP-1s, short for glucagon-like peptide-1 receptor agonists, covered by insurance when used strictly for weight loss. But there are weight and health requirements, and those who already get GLP-1s covered for diseases like diabetes and sleep apnea won’t qualify.

, the administrator of the Centers for Medicare & Medicaid Services, said he hopes the program can help his agency collect data to potentially work toward longer-term coverage, while providing immediate relief to cash-strapped older Americans.

“The sheer cost of these medications is a huge barrier to access,” he said in a call with reporters. “That ends today.”

Eligibility is based on BMI and other conditions

Of the more than 70 million Americans enrolled in Medicare, at least 10 million are overweight or obese, said Juliette Cubanski, vice president and director of the program on Medicare policy at the healthcare research nonprofit KFF. But, she said, a narrower slice of that group will have access to this program.

There's no good data on how many people it can benefit — and Oz declined to speculate on the number with reporters. He said data from the program will reveal how many eligible beneficiaries choose to take the drugs, a number his team is keen to learn.

To qualify, besides having Medicare drug coverage, you must have a body mass index of 35 or higher, or a BMI of 27 or higher alongside another health condition, such as a past heart attack or stroke, prediabetes or another from . BMI measurements are counted at the start of GLP-1 therapy — so even people who fall below the threshold now can qualify if they can show they had a high enough BMI when they began taking the drugs.

Medicare beneficiaries who have sleep apnea, diabetes or fatty liver disease can’t access the program, but their Medicare Part D insurance might cover their GLP-1s separately based on those diagnoses.

If you think you might qualify, the first step is to contact your health care provider, CMS says on its website. The provider must send a prescription for one of the covered GLP-1 drugs to a pharmacy and fill out a prior authorization form.

Only some GLP-1s are included

The covered medications include drugmaker Eli Lilly’s Foundayo tablets and Zepbound KwikPens and Novo Nordisk’s Wegovy injections and tablets. Those GLP-1s have been approved by the Food and Drug Administration for weight loss, Cubanski said.

For those in the program, the cost is $50 per month, regardless of dosage. But those payments won’t contribute to their insurance deductibles or out-of-pocket maximums. That’s because Medicare, rather than the Part D insurer, is subsidizing the prescription.

Longer-term coverage of GLP-1s remains uncertain

The program is scheduled to sunset after Dec. 31, 2027. And since Congress hasn’t authorized Medicare to cover weight loss drugs permanently, the federal government is limited in its options to keep the access flowing.

Congress could pass a law to allow the drugs to be covered. CMS also could move forward with a different, voluntary pilot program for covering the drugs called BALANCE, which the agency indefinitely delayed earlier this year when many Part D insurers were reluctant to sign up.

Oz told reporters that CMS plans to “carefully track participation and outcomes” to see whether an extension of the Bridge program or another solution is the best way to move forward. He told The Associated Press a federal law permanently allowing the coverage is “not essential right now” but something “for Congress to debate amongst themselves.”

“We can’t decide what’s going to happen long term with Bridge until we see some of the data,” he said, noting that with drug companies to lower costs are ongoing.

Program is life-changing for some, frustrating for others

GLP-1s have soared in popularity in recent years, and they've spurred dramatic weight loss in many patients. But their cost — sometimes hundreds of dollars a month for higher doses — has been a barrier.

For 78-year-old California resident Gloria Dralla, who told the AP she’s lost some 40 pounds after buying lower-cost Wegovy in Europe, the Bridge program means being able to continue a treatment that has improved her life.

“This drug should be made available at a reasonable price for everybody who’s got weight loss problems,” she said.

But not everyone will have access to the drugs at an affordable price. Katie Smith, 71, in Virginia isn’t so sure she will be eligible for the program. She has a BMI of 33 but isn’t sure if she has another health condition that would allow her to meet the requirements.

Smith, whose mobility and ability to exercise were severely limited by a spinal cord injury in her 20s, said she has looked into getting the medications but was quoted $700 a month, a price she can't afford.

“I cannot tell you how frustrated I am,” she said. “I have the drive and I have the willingness and I have the motivation, but I have not been able to lose weight in all the conventional ways.”